Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

← catalyst calendar

NCT07214532 · readout in 4,106 d

Sponsored by Natera, Inc. (industry) · NTRA — their whole pipeline →.

Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
725estimated
Sites
48
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2026-05-08actualWhen the study began enrolling
Primary completion2037-11-15estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2037-12-30estimatedThe whole study's end, after follow-up
First posted2025-10-09actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-13actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Breast Neoplasms
  • Carcinoma, Ductal, Breast
  • Receptors, Estrogen (for ER-positive Requirement)

Intervention

  • Device: ctDNA-Guided Treatment Strategy

Primary outcome

what the primary-completion date above is the date OF
Invasive Disease-Free Survival
measured From the date of surgery up to 9 years

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · NTRA's whole pipeline · Catalyst calendar · Every registered study · What changed